{"id":952512,"date":"2026-04-17T08:34:07","date_gmt":"2026-04-17T12:34:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-declares-second-quarter-2026-dividend\/"},"modified":"2026-04-17T08:34:07","modified_gmt":"2026-04-17T12:34:07","slug":"royalty-pharma-declares-second-quarter-2026-dividend","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-declares-second-quarter-2026-dividend\/","title":{"rendered":"Royalty Pharma Declares Second Quarter 2026 Dividend"},"content":{"rendered":"
\n

NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) — The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2026 of $0.235 per Class A ordinary share.<\/p>\n

The dividend will be paid on June 10, 2026, to shareholders of record at the close of business on May 15, 2026.<\/p>\n

\n About Royalty Pharma <\/strong>\n <\/p>\n

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry\u2019s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly \u2013 directly when it partners with companies to co fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma\u2019s current portfolio includes royalties on more than 35 commercial products, including Vertex\u2019s Trikafta and Alyftrek, GSK\u2019s Trelegy, Roche\u2019s Evrysdi, Johnson & Johnson\u2019s Tremfya, Biogen\u2019s Tysabri and Spinraza, Servier\u2019s Voranigo, AbbVie and Johnson & Johnson\u2019s Imbruvica, Astellas and Pfizer\u2019s Xtandi, Pfizer\u2019s Nurtec ODT, and Gilead\u2019s Trodelvy, and 19 development-stage product candidates. For more information, visit www.royaltypharma.com<\/a>.\u00a0\u00a0\u00a0<\/p>\n

\n Royalty Pharma Investor Relations and Communications<\/strong>\n <\/p>\n

+1 (212) 883-6637
ir@royaltypharma.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) — The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2026 of $0.235 per Class A ordinary share. The dividend will be paid on June 10, 2026, to shareholders of record at the close of business on May 15, 2026. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based … <\/p>\n

Continue reading “Royalty Pharma Declares Second Quarter 2026 Dividend”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-952512","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nRoyalty Pharma Declares Second Quarter 2026 Dividend - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-declares-second-quarter-2026-dividend\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Royalty Pharma Declares Second Quarter 2026 Dividend - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) — The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2026 of $0.235 per Class A ordinary share. The dividend will be paid on June 10, 2026, to shareholders of record at the close of business on May 15, 2026. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based … Continue reading "Royalty Pharma Declares Second Quarter 2026 Dividend"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-declares-second-quarter-2026-dividend\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-17T12:34:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTk1MSM3NTQwNTA2IzUwMDEwNTI2NA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/royalty-pharma-declares-second-quarter-2026-dividend\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/royalty-pharma-declares-second-quarter-2026-dividend\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Royalty Pharma Declares Second Quarter 2026 Dividend\",\"datePublished\":\"2026-04-17T12:34:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/royalty-pharma-declares-second-quarter-2026-dividend\\\/\"},\"wordCount\":252,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/royalty-pharma-declares-second-quarter-2026-dividend\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MTk1MSM3NTQwNTA2IzUwMDEwNTI2NA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/royalty-pharma-declares-second-quarter-2026-dividend\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/royalty-pharma-declares-second-quarter-2026-dividend\\\/\",\"name\":\"Royalty Pharma Declares Second Quarter 2026 Dividend - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/royalty-pharma-declares-second-quarter-2026-dividend\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/royalty-pharma-declares-second-quarter-2026-dividend\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MTk1MSM3NTQwNTA2IzUwMDEwNTI2NA==\",\"datePublished\":\"2026-04-17T12:34:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/royalty-pharma-declares-second-quarter-2026-dividend\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/royalty-pharma-declares-second-quarter-2026-dividend\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/royalty-pharma-declares-second-quarter-2026-dividend\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MTk1MSM3NTQwNTA2IzUwMDEwNTI2NA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MTk1MSM3NTQwNTA2IzUwMDEwNTI2NA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/royalty-pharma-declares-second-quarter-2026-dividend\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Royalty Pharma Declares Second Quarter 2026 Dividend\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Royalty Pharma Declares Second Quarter 2026 Dividend - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-declares-second-quarter-2026-dividend\/","og_locale":"en_US","og_type":"article","og_title":"Royalty Pharma Declares Second Quarter 2026 Dividend - Market Newsdesk","og_description":"NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) — The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2026 of $0.235 per Class A ordinary share. The dividend will be paid on June 10, 2026, to shareholders of record at the close of business on May 15, 2026. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based … Continue reading \"Royalty Pharma Declares Second Quarter 2026 Dividend\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-declares-second-quarter-2026-dividend\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-17T12:34:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTk1MSM3NTQwNTA2IzUwMDEwNTI2NA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-declares-second-quarter-2026-dividend\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-declares-second-quarter-2026-dividend\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Royalty Pharma Declares Second Quarter 2026 Dividend","datePublished":"2026-04-17T12:34:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-declares-second-quarter-2026-dividend\/"},"wordCount":252,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-declares-second-quarter-2026-dividend\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTk1MSM3NTQwNTA2IzUwMDEwNTI2NA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-declares-second-quarter-2026-dividend\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-declares-second-quarter-2026-dividend\/","name":"Royalty Pharma Declares Second Quarter 2026 Dividend - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-declares-second-quarter-2026-dividend\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-declares-second-quarter-2026-dividend\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTk1MSM3NTQwNTA2IzUwMDEwNTI2NA==","datePublished":"2026-04-17T12:34:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-declares-second-quarter-2026-dividend\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-declares-second-quarter-2026-dividend\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-declares-second-quarter-2026-dividend\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTk1MSM3NTQwNTA2IzUwMDEwNTI2NA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTk1MSM3NTQwNTA2IzUwMDEwNTI2NA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-declares-second-quarter-2026-dividend\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Royalty Pharma Declares Second Quarter 2026 Dividend"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/952512","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=952512"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/952512\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=952512"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=952512"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=952512"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}